Lower risk of SARS-CoV2 infection in individuals with severe mental disorders on antipsychotic treatment: A retrospective epidemiological study in a representative Spanish population
- PMID: 33631466
- PMCID: PMC7894093
- DOI: 10.1016/j.schres.2021.02.002
Lower risk of SARS-CoV2 infection in individuals with severe mental disorders on antipsychotic treatment: A retrospective epidemiological study in a representative Spanish population
Conflict of interest statement
Declaration of competing interest The authors have no conflicts of interest concerning the subject of the study.
Comment in
-
Letter on: "Lower risk of SARS-CoV2 infection in individuals with severe mental disorders on antipsychotic treatment: A retrospective epidemiological study in a representative Spanish population".Schizophr Res. 2021 Jul;233:97-98. doi: 10.1016/j.schres.2021.06.036. Epub 2021 Jun 26. Schizophr Res. 2021. PMID: 34217549 Free PMC article. No abstract available.
-
Can antipsychotic use protect from COVID-19?Schizophr Res. 2021 Oct;236:1-2. doi: 10.1016/j.schres.2021.07.035. Epub 2021 Jul 30. Schizophr Res. 2021. PMID: 34352504 Free PMC article. No abstract available.
-
An overall protective effect of antipsychotic drugs against COVID-19 seems implausible.Schizophr Res. 2022 May;243:486-488. doi: 10.1016/j.schres.2021.12.020. Epub 2021 Dec 22. Schizophr Res. 2022. PMID: 34969568 Free PMC article. No abstract available.
References
-
- Dyall J., Gross R., Kindrachuk J., Johnson R.F., Olinger G.G.J., Hensley L.E., Frieman M.B., Jahrling P.B. Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies. Drugs. 2017;77:1935–1966. doi: 10.1007/s40265-017-0830-1. - DOI - PMC - PubMed
-
- Lee S.W., Yang J.M., Moon S.Y., Yoo I.K., Ha E.K., Kim S.Y., Park U.M., Choi S., Lee S.-H., Ahn Y.M., Kim J.-M., Koh H.Y., Yon D.K. Association between mental illness and COVID-19 susceptibility and clinical outcomes in South Korea: a nationwide cohort study. Lancet Psychiatry. 2020;7:1025–1031. doi: 10.1016/S2215-0366(20)30421-1. - DOI - PMC - PubMed
-
- Riva L., Yuan S., Yin X., Martin-Sancho L., Matsunaga N., Pache L., Burgstaller-Muehlbacher S., De Jesus P.D., Teriete P., Hull M.V., Chang M.W., Chan J.F.-W., Cao J., Poon V.K.-M., Herbert K.M., Cheng K., Nguyen T.-T.H., Rubanov A., Pu Y., Nguyen C., Choi A., Rathnasinghe R., Schotsaert M., Miorin L., Dejosez M., Zwaka T.P., Sit K.-Y., Martinez-Sobrido L., Liu W.-C., White K.M., Chapman M.E., Lendy E.K., Glynne R.J., Albrecht R., Ruppin E., Mesecar A.D., Johnson J.R., Benner C., Sun R., Schultz P.G., Su A.I., García-Sastre A., Chatterjee A.K., Yuen K.-Y., Chanda S.K. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature. 2020;586:113–119. doi: 10.1038/s41586-020-2577-1. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
